These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30061228)

  • 1. Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
    Wińska P; Skierka K; Łukowska-Chojnacka E; Koronkiewicz M; Cieśla J; Bretner M
    Anticancer Res; 2018 Aug; 38(8):4617-4627. PubMed ID: 30061228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
    Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
    Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Interactions of 5-Fluorouracil with Inhibitors of Protein Kinase CK2 Correlate with p38 MAPK Activation and FAK Inhibition in the Triple-Negative Breast Cancer Cell Line.
    Wińska P; Karatsai O; Staniszewska M; Koronkiewicz M; Chojnacki K; Rędowicz MJ
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
    Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
    Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1
    Chojnacki K; Wińska P; Karatsai O; Koronkiewicz M; Milner-Krawczyk M; Wielechowska M; Rędowicz MJ; Bretner M; Borowiecki P
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, in vitro antiproliferative activity and kinase profile of new benzimidazole and benzotriazole derivatives.
    Chojnacki K; Wińska P; Skierka K; Wielechowska M; Bretner M
    Bioorg Chem; 2017 Jun; 72():1-10. PubMed ID: 28340404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro.
    Koronkiewicz M; Chilmonczyk Z; Kazimierczuk Z
    Anticancer Res; 2013 Nov; 33(11):4891-9. PubMed ID: 24222126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
    Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
    Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase.
    Chojnacki K; Lindenblatt D; Wińska P; Wielechowska M; Toelzer C; Niefind K; Bretner M
    Bioorg Chem; 2021 Jan; 106():104502. PubMed ID: 33317841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the protein kinase inhibitor 1-(β-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines.
    Koronkiewicz M; Kazimierczuk Z; Orzeszko A
    BMC Cancer; 2022 Oct; 22(1):1069. PubMed ID: 36243702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil.
    Vinod BS; Antony J; Nair HH; Puliyappadamba VT; Saikia M; Narayanan SS; Bevin A; Anto RJ
    Cell Death Dis; 2013 Feb; 4(2):e505. PubMed ID: 23429291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
    Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells.
    Kaminska B; Ellert-Miklaszewska A; Oberbek A; Wisniewski P; Kaza B; Makowska M; Bretner M; Kazimierczuk Z
    Int J Oncol; 2009 Nov; 35(5):1091-100. PubMed ID: 19787263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
    Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
    J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and exploitation of CK2 inhibitors.
    Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
    Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
    Coudray AM; Louvet C; Kornprobst M; Raymond E; André T; Tournigand C; Faivre S; De Gramont A; Larsen AK; Gespach C
    Int J Oncol; 2005 Aug; 27(2):553-61. PubMed ID: 16010439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks.
    Schneider CC; Hessenauer A; Götz C; Montenarh M
    Oncol Rep; 2009 Jun; 21(6):1593-7. PubMed ID: 19424641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Protein Kinase CK2 Affects Thymidylate Synthesis Cycle Enzyme Level and Distribution in Human Cancer Cells.
    Wińska P; Widło Ł; Senkara E; Koronkiewicz M; Cieśla JM; Krzyśko A; Skierka K; Cieśla J
    Front Mol Biosci; 2022; 9():847829. PubMed ID: 35281258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole.
    Bretner M; Najda-Bernatowicz A; Łebska M; Muszyńska G; Kilanowicz A; Sapota A
    Mol Cell Biochem; 2008 Sep; 316(1-2):87-9. PubMed ID: 18548199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.